Anti-Human SOST Single Domain Antibody (TAB-392CT), Research Grade Biosimilar (CAT#: TAB-392CT)

1. Q 1: What research applications does the Anti-Human SOST Antibody support?

   A: The Anti-Human SOST Single Domain Antibody is primarily used in osteoporosis and related bone disease studies, as sclerostin is a negative regulator of bone formation. This antibody is employed in immunoassay techniques such as Western Blot, ELISA, and Flow Cytometry to identify and quantify SOST protein levels in biological samples, furthering our understanding of bone metabolism and potential therapeutic avenues.

2. Q 2: How does sclerostin contribute to disease processes?

   A: Sclerostin, encoded by the SOST gene, inhibits the Wnt signaling pathway, which is vital for bone formation. Reduced activity or expression of sclerostin leads to increased bone mass, whereas its overexpression can contribute to conditions like osteoporosis by suppressing bone formation. Anti-sclerostin antibodies, by neutralizing its activity, can creatively modulate these pathways for therapeutic benefits, especially in degenerative bone diseases.

3. Q 3: What diseases can be further studied using the anti-SOST antibody?

   A: Aside from osteoporosis, the antibody is instrumental in studying multiple myeloma, Paget's disease, osteopenia, and other metabolic bone disorders. Disruptions in sclerostin levels are significant in these diseases, making this antibody a valuable tool for research and potential therapeutic intervention studies.

View the frequently asked questions answered by Creative Biolabs Support.